Could cause temporary or reversible harm; serious harm is unlikely.
Presence of particulate matter: potential presence of metal particulates in the product.
| Brand name | NOXAFIL |
| Generic name | POSACONAZOLE |
| Active ingredient(s) | POSACONAZOLE |
| Distributed by / for | Merck Sharp & Doohme LLC, Rahway, NJ 07056 USA |
| NDC | 0085-2224-02 |
| Full product label | Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway, NJ 07056 USA, Manufactured by: N.V. Organon, 5349 AB Oss, The Netherlands, a subsidiary of Organon & Co., Jersey City, NJ 07302, USA NDC 0085-2224-02. |
| Recalling firm | Merck Sharp & Dohme LLC |
| Distribution | Nationwide in the USA |
| Quantity | 845 kits |
| Recall initiated | 2025-12-12 |
| Report date | 2025-12-31 |
| Recall completed | — |
| Recall number | D-0242-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Wilson NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗